Cancerous Target Suppliers Serving Estonia

PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...

Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...

ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes ...

We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...

Nuclidium AG specializes in leveraging the unique properties of copper radionuclides in conjunction with tumor-specific molecules to enhance the precision, performance, and accessibility of targeted radiotherapy and diagnostics. Their proprietary ...

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...

Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...

Focal Healthcare is a world-class medical device company dedicated to improving the physician and patient experience from prostate cancer diagnosis to treatment. Throughout his career, Chicuong realized that there were many inefficiencies, ...

Based in Perth, Western Australia, Epichem was established in 2003 and was driven by a desire to solve difficult synthetic chemistry problems and to provide jobs for home grown PhD organic chemists. We are Australia’s leading provider of synthetic ...

Taiho Oncology, Inc. specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a ...

SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes. SurgiMab was ...

MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...

Breath science is rapidly growing — and we are growing with it Advances in analytical chemistry have accelerated the pace of exhaled biomarker research. New breath diagnostics targeting cancer, asthma, infections, and other conditions are rapidly ...

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...

Lightpoint Medical is a technology leader in targeted cancer surgery. We are developing miniaturized imaging and sensing tools for more precise intra-operative cancer detection. Our mission is to improve the lives of people with cancer by ...

We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable. We are developing Signal-X™, a multi-cancer platform able to detect various types of high-burden ...

Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...

Novel therapeutics are lacking for Brain Cancer. Only four of the 217 FDA-approved oncology medicines are indicated for life-threatening brain cancers. The most recent approval was in 2009 and did not extend life expectancy. Patients deserve better ...

Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. A family-owned company, bioMérieux has grown to become a world leader in the ...